132 related articles for article (PubMed ID: 35603926)
21. Muscle mass, assessed at diagnosis by L3-CT scan as a prognostic marker of clinical outcomes in patients with gastric cancer: A systematic review and meta-analysis.
Rinninella E; Cintoni M; Raoul P; Pozzo C; Strippoli A; Bria E; Tortora G; Gasbarrini A; Mele MC
Clin Nutr; 2020 Jul; 39(7):2045-2054. PubMed ID: 31718876
[TBL] [Abstract][Full Text] [Related]
22. Computed Tomography-Defined Fat Composition as a Prognostic Marker in Gastric Adenocarcinoma: A Systematic Review and Meta-Analysis.
Meyer HJ; Wienke A; Pech M; Surov A
Dig Dis; 2023; 41(2):177-186. PubMed ID: 36228589
[TBL] [Abstract][Full Text] [Related]
23. A comparison between triplet and doublet chemotherapy in improving the survival of patients with advanced gastric cancer: a systematic review and meta-analysis.
Guo X; Zhao F; Ma X; Shen G; Ren D; Zheng F; Du F; Wang Z; Ahmad R; Yuan X; Zhao J; Zhao J
BMC Cancer; 2019 Nov; 19(1):1125. PubMed ID: 31747911
[TBL] [Abstract][Full Text] [Related]
24. Prognostic significance of CT-determined sarcopenia in patients with advanced gastric cancer.
Lee JS; Kim YS; Kim EY; Jin W
PLoS One; 2018; 13(8):e0202700. PubMed ID: 30125312
[TBL] [Abstract][Full Text] [Related]
25. The Predictive Value of Low Skeletal Muscle Mass Assessed on Cross-Sectional Imaging for Anti-Cancer Drug Toxicity: A Systematic Review and Meta-Analysis.
Huiskamp LFJ; Chargi N; Devriese LA; May AM; Huitema ADR; de Bree R
J Clin Med; 2020 Nov; 9(11):. PubMed ID: 33238530
[TBL] [Abstract][Full Text] [Related]
26. Loss of skeletal muscle mass during palliative chemotherapy is a poor prognostic factor in patients with advanced gastric cancer.
Park SE; Choi JH; Park JY; Kim BJ; Kim JG; Kim JW; Park JM; Chi KC; Hwang IG
Sci Rep; 2020 Oct; 10(1):17683. PubMed ID: 33077864
[TBL] [Abstract][Full Text] [Related]
27. Blood neutrophil-lymphocyte ratio predicts survival for stages III-IV gastric cancer treated with neoadjuvant chemotherapy.
Jin H; Zhang G; Liu X; Liu X; Chen C; Yu H; Huang X; Zhang Q; Yu J
World J Surg Oncol; 2013 May; 11():112. PubMed ID: 23705622
[TBL] [Abstract][Full Text] [Related]
28. Low skeletal muscle mass and post-operative complications after surgery for liver malignancies: a meta-analysis.
Thormann M; Omari J; Pech M; Damm R; Croner R; Perrakis A; Strobel A; Wienke A; Surov A
Langenbecks Arch Surg; 2022 Jun; 407(4):1369-1379. PubMed ID: 35583832
[TBL] [Abstract][Full Text] [Related]
29. Prognostic significance of a systemic inflammatory response in patients receiving first-line palliative chemotherapy for recurred or metastatic gastric cancer.
Hwang JE; Kim HN; Kim DE; Choi HJ; Jung SH; Shim HJ; Bae WK; Hwang EC; Cho SH; Chung IJ
BMC Cancer; 2011 Nov; 11():489. PubMed ID: 22103888
[TBL] [Abstract][Full Text] [Related]
30. Impact of skeletal muscle mass in patients with unresectable gastric cancer who received palliative first-line chemotherapy based on 5-fluorouracil.
Matsunaga T; Saito H; Miyauchi W; Shishido Y; Miyatani K; Morimoto M; Murakami Y; Hanaki T; Kihara K; Yamamoto M; Tokuyasu N; Takano S; Sakamoto T; Hasegawa T; Fujiwara Y
BMC Cancer; 2021 Nov; 21(1):1219. PubMed ID: 34774016
[TBL] [Abstract][Full Text] [Related]
31. The prognostic significance of the increase in the serum M30 and M65 values after chemotherapy and relationship between these values and clinicopathological factors in patients with advanced gastric cancer.
Bilici A; Ustaalioglu BB; Ercan S; Seker M; Yilmaz BE; Orcun A; Gumus M
Tumour Biol; 2012 Dec; 33(6):2201-8. PubMed ID: 22890829
[TBL] [Abstract][Full Text] [Related]
32. Prognostic Impact of Sarcopenia on Clinical Outcomes in Malignancies Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis.
Li S; Wang T; Tong G; Li X; You D; Cong M
Front Oncol; 2021; 11():726257. PubMed ID: 34513704
[TBL] [Abstract][Full Text] [Related]
33. Prognostic role of body composition parameters in gastric/gastroesophageal junction cancer patients from the EXPAND trial.
Hacker UT; Hasenclever D; Linder N; Stocker G; Chung HC; Kang YK; Moehler M; Busse H; Lordick F
J Cachexia Sarcopenia Muscle; 2020 Feb; 11(1):135-144. PubMed ID: 31464089
[TBL] [Abstract][Full Text] [Related]
34. Prevalence and mortality risk of low skeletal muscle mass in critically ill patients: an updated systematic review and meta-analysis.
Yang H; Wan XX; Ma H; Li Z; Weng L; Xia Y; Zhang XM
Front Nutr; 2023; 10():1117558. PubMed ID: 37252244
[TBL] [Abstract][Full Text] [Related]
35. [Safety and efficacy of adjuvant chemotherapy with oxaliplatin and S-1 for patients with locally advanced gastric cancer after D2 lymph nodes dissection].
Bao YD; Zhang H; Dong L; Jiang KW; Ye YJ; Wang S; Zhou J
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):145-152. PubMed ID: 33508920
[No Abstract] [Full Text] [Related]
36. Long-Term Outcomes of Neoadjuvant Chemotherapy in Locally Advanced Gastric Cancer/Esophagogastric Junction Cancer: A Systematic Review and Meta-Analysis.
Wu F; Hong J; Du N; Wang Y; Chen J; He Y; Chen P
Anticancer Agents Med Chem; 2022; 22(1):143-151. PubMed ID: 33719964
[TBL] [Abstract][Full Text] [Related]
37. Low skeletal muscle mass as a risk factor for postoperative delirium in elderly patients undergoing colorectal cancer surgery.
Mosk CA; van Vugt JLA; de Jonge H; Witjes CD; Buettner S; Ijzermans JN; van der Laan L
Clin Interv Aging; 2018; 13():2097-2106. PubMed ID: 30425464
[TBL] [Abstract][Full Text] [Related]
38. The impact of sarcopenia and decrease in skeletal muscle mass in patients with advanced pancreatic cancer during FOLFIRINOX therapy.
Uemura S; Iwashita T; Ichikawa H; Iwasa Y; Mita N; Shiraki M; Shimizu M
Br J Nutr; 2021 May; 125(10):1140-1147. PubMed ID: 32883372
[TBL] [Abstract][Full Text] [Related]
39. Postoperative nodal status and diffuse-type histology are independent prognostic factors in resectable advanced gastric carcinomas after preoperative chemotherapy.
Koh YW; Park YS; Ryu MH; Ryoo BY; Park HJ; Yook JH; Kim BS; Kang YK
Am J Surg Pathol; 2013 Jul; 37(7):1022-9. PubMed ID: 23715160
[TBL] [Abstract][Full Text] [Related]
40. Class III β-tubulin is a predictive marker for taxane-based chemotherapy in recurrent and metastatic gastric cancer.
Hwang JE; Hong JY; Kim K; Kim SH; Choi WY; Kim MJ; Jung SH; Shim HJ; Bae WK; Hwang EC; Lee KH; Lee JH; Cho SH; Chung IJ
BMC Cancer; 2013 Sep; 13():431. PubMed ID: 24053422
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
